Purinergic system dysfunction in mood disorders: A key target for developing improved therapeutics

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 57, Issue , 2015, Pages 117-131

  Ortiz, Robin ^a   Ulrich, Henning ^b   Zarate, Carlos A ^a   Machado Vieira, Rodrigo ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bipolar disorder; Depression; Mania; Purines; Treatment; Uric acid

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; ANTIDEPRESSANT AGENT; CYCLOHEXYLADENOSINE; GUANINE; JNJ 4795567; N6 [2 (3,5 DIMETHOXYPHENYL) 2 (METHYLPHENYL)ETHYL]ADENOSINE; PRELADENANT; PURINERGIC P2 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SCH 412348; UNCLASSIFIED DRUG; URIC ACID; XANTHINE OXIDASE; ZOTEPINE; BIOLOGICAL MARKER; GUANOSINE; PSYCHOTROPIC AGENT; PURINERGIC RECEPTOR;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ASTROCYTE; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; BRAIN LEVEL; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; KIDNEY CLEARANCE; LOCOMOTION; MEMORY DISORDER; MICROGLIA; MOOD DISORDER; NERVOUS SYSTEM FUNCTION; NEUROLOGIC DISEASE; NONHUMAN; P2X7 RECEPTOR GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PURINERGIC SYSTEM DYSFUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANQUILIZING ACTIVITY; ANIMAL; BIOLOGICAL MODEL; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOOD DISORDERS; NEUROIMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ANIMALS; BIOMARKERS; GUANOSINE; HUMANS; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; MOOD DISORDERS; NEUROIMAGING; PSYCHOTROPIC DRUGS; RECEPTORS, PURINERGIC;

EID: 84909989416     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.10.016     Document Type: Review

References (202)

1. Agren H., Niklasson F., Hallgren R. Brain purinergic activity linked with depressive symptomatology: hypoxanthine and xanthine in CSF of patients with major depressive disorders. Psychiatry Res 1983, 9:179-189.
2. Akhondzadeh S., Milajerdi M.R., Amini H., Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006, 8:485-489.
3. Almeida R.F., Cereser V.H., Faraco R.B., Bohmer A.E., Souza D.O., Ganzella M. Systemic administration of GMP induces anxiolytic-like behavior in rats. Pharmacol Biochem Behav 2010, 96:306-311.
4. Alsene K., Deckert J., Sand P., de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003, 28:1694-1702.
5. Anumonye A., Reading H.W., Knight F., Ashcroft G.W. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet 1968, 1:1290-1293.
6. Backlund L., Nikamo P., Hukic D.S., Ek I.R., Transkman-Bendz L., Landen M., et al. Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar Disord 2011, 13:500-508.
7. Backlund L., Lavebratt C., Frisen L., Nikamo P., Hukic Sudic D., Traskman-Bendz L., et al. P2RX7: expression responds to sleep deprivation and associates with rapid cycling in bipolar disorder type 1. PLoS One 2012, 7:e43057.
8. Bair M.J., Robinson R.L., Katon W., Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003, 163:2433-2445.
9. Baker J.G., Hill S.J. A comparison of the antagonist affinities for the Gi- and Gs-coupled states of the human adenosine A1-receptor. J Pharmacol Exp Ther 2007, 320:218-228.
10. Barden N., Harvey M., Gagne B., Shink E., Tremblay M., Raymond C., et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:374-382.
11. Basso A.M., Bratcher N.A., Harris R.R., Jarvis M.F., Decker M.W., Rueter L.E. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res 2009, 198:83-90.
12. Bauer A., Ishiwata K. Adenosine receptor ligands and PET imaging of the CNS. Handb Exp Pharmacol 2009, 617-642.
13. Bennett M.R. Synaptic P2X7 receptor regenerative-loop hypothesis for depression. Aust N Z J Psychiatry 2007, 41:563-571.
14. Bhattacharya A., Wang Q., Ao H., Shoblock J.R., Lord B., Aluisio L., et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 2013, 170:624-640.
15. Biber K., Fiebich B.L., Gebicke-Härter P., van Calker D. Carbamazepine-induced upregulation of adenosine A1-receptors in astrocyte cultures affects coupling to the phosphoinositol signaling pathway. Neuropsychopharmacology 1999, 20:271-278.
16. Bishnoi R.J. Clinical potential of allopurinol in the treatment of bipolar disorder. Indian J Psychol Med 2014, 36:218-220.
17. Blardi P., de Lalla A., Urso R., Auteri A., Dell'Erba A., Bossini L., et al. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J Clin Psychopharmacol 2005, 25:262-266.
18. Bortolato M., Yardley M.M., Khoja S., Godar S.C., Asatryan L., Finn D.A., et al. Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin. Int J Neuropsychopharmacol 2013, 16:1059-1070.
19. Boucher A.A., Arnold J.C., Hunt G.E., Spiro A., Spencer J., Brown C., et al. Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 2011, 189:170-177.
20. Bowman G.L., Shannon J., Frei B., Kaye J.A., Quinn J.F. Uric acid as a CNS antioxidant. J Alzheimers Dis 2010, 19:1331-1336.
21. Brooks S.C., Linn J.J., Disney N. Serotonin, folic acid, and uric acid metabolism in the diagnosis of neuropsychiatric disorders. Biol Psychiatry 1978, 13:671-684.
22. Brown B.L., Salway J.G., Albano J.D., Hullin R.P., Ekins R.P. Urinary excretion of cyclic AMP and manic-depressive psychosis. Br J Psychiatry 1972, 120:405-408.
23. Brown A.K., Fujita M., Fujimura Y., Liow J.S., Stabin M., Ryu Y.H., et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med 2007, 48:2072-2079.
24. Burnstock G. Purinergic nerves. Pharmacol Rev 1972, 24:509-581.
25. Burnstock G. The purinergic nerve hypothesis. Ciba Found Symp 1977, 48:295-314.
26. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007, 87:659-797.
27. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 2008, 7:575-590.
28. Burnstock G. Introduction to purinergic signalling in the brain. Adv Exp Med Biol 2013, 986:1-12.
29. Burnstock G. Purinergic signalling in endocrine organs. Purinergic Signal 2014, 10:189-231.
30. Burnstock G., Kennedy C. P2X receptors in health and disease. Adv Pharmacol 2011, 61:333-372.
31. Cao X., Li L.P., Wang Q., Wu Q., Hu H.H., Zhang M., et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med 2013, 19:773-777.
32. Caporali M.G., Popoli P., de Carolis A.S. Is the purinergic system involved in the control of pathological movements?. Eur J Pharmacol 1987, 137:247-249.
33. Chan H.Y., Jou S.H., Juang Y.Y., Chang C.J., Chen J.J., Chen C.H., et al. A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania. Psychiatry Clin Neurosci 2010, 64:162-169.
34. Chaudhari K., Khanzode S., Khanzode S., Dakhale G., Saoji A., Sarode S. Clinical correlation of alteration of endogenous antioxidant-uric acid level in major depressive disorder. Indian J Clin Biochem 2010, 25:77-81.
35. Chen J.F., Beilstein M., Xu Y.H., Turner T.J., Moratalla R., Standaert D.G., et al. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 2000, 97:195-204.
36. Christiansen L., Tan Q., Kruse T.A., McGue M., Christensen K. Candidate region linkage analysis in twins discordant or concordant for depression symptomatology. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:581-584.
37. Chung K.H., Huang C.C., Lin H.C. Increased risk of gout among patients with bipolar disorder: a nationwide population-based study. Psychiatry Res 2010, 180:147-150.
38. Cordeaux Y., Ijzerman A.P., Hill S.J. Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol 2004, 143:705-714.
39. Crema L.M., Pettenuzzo L.F., Schlabitz M., Diehl L., Hoppe J., Mestriner R., et al. The effect of unpredictable chronic mild stress on depressive-like behavior and on hippocampal A1 and striatal A2A adenosine receptors. Physiol Behav 2013, 109:1-7.
40. Csolle C., Baranyi M., Zsilla G., Kittel A., Goloncser F., Illes P., et al. Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors. PLoS One 2013, 8:e66547.
41. Cunha R.A., Ferre S., Vaugeois J.M., Chen J.F. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008, 14:1512-1524.
42. Curtis D., Kalsi G., Brynjolfsson J., McInnis M., O'Neill J., Smyth C., et al. Genome scan of pedigrees multiply affected with bipolar disorder provides further support for the presence of a susceptibility locus on chromosome 12q23-q24, and suggests the presence of additional loci on 1p and 1q. Psychiatr Genet 2003, 13:77-84.
43. De Berardis D., Conti C.M., Campanella D., Carano A., Di Giuseppe B., Valchera A., et al. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J Biol Regul Homeost Agents 2008, 22:195-200.
44. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry 1995, 152:915-918.
45. Dias R.B., Rombo D.M., Ribeiro J.A., Henley J.M., Sebastiao A.M. Adenosine: setting the stage for plasticity. Trends Neurosci 2013, 36:248-257.
46. El Yacoubi M., Ledent C., Parmentier M., Bertorelli R., Ongini E., Costentin J., et al. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 2001, 134:68-77.
47. El Yacoubi M., Ledent C., Parmentier M., Costentin J., Vaugeois J.M. Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade. Neuropharmacology 2003, 45:977-985.
48. Elmenhorst D., Basheer R., McCarley R.W., Bauer A. Sleep deprivation increases A(1) adenosine receptor density in the rat brain. Brain Res 2009, 1258:53-58.
49. Elmenhorst D., Meyer P.T., Matusch A., Winz O.H., Bauer A. Caffeine occupancy of human cerebral A1 adenosine receptors: in vivo quantification with 18F-CPFPX and PET. J Nucl Med 2012, 53:1723-1729.
50. Erhardt A., Lucae S., Unschuld P.G., Ising M., Kern N., Salyakina D., et al. Association of polymorphisms in P2RX7 and CaMKKb with anxiety disorders. J Affect Disord 2007, 101:159-168.
51. Ewald H., Kruse T.A., Mors O. Genome wide scan using homozygosity mapping and linkage analyses of a single pedigree with affective disorder suggests oligogenic inheritance. Am J Med Genet B Neuropsychiatr Genet 2003, 120B:63-71.
52. Fan A., Berg A., Bresee C., Glassman L.H., Rapaport M.H. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord 2012, 14:206-210.
53. Fedorova I.M., Jacobson M.A., Basile A., Jacobson K.A. Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol 2003, 23:431-447.
54. Feduccia A.A., Wang Y., Simms J.A., Yi H.Y., Li R., Bjeldanes L., et al. Locomotor activation by theacrine, a purine alkaloid structurally similar to caffeine: involvement of adenosine and dopamine receptors. Pharmacol Biochem Behav 2012, 102:241-248.
55. Ferrari D., Stroh C., Schulze-Osthoff K. P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem 1999, 274:13205-13210.
56. Fields R.D., Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 2006, 7:423-436.
57. Forester B.P., Harper D.G., Jensen J.E., Ravichandran C., Jordan B., Renshaw P.F., et al. 31Phosphorus magnetic resonance spectroscopy study of tissue specific changes in high energy phosphates before and after sertraline treatment of geriatric depression. Int J Geriatr Psychiatry 2009, 24:788-797.
58. Franke H., Krugel U., Illes P. P2 receptors and neuronal injury. Pflugers Arch 2006, 452:622-644.
59. Fredholm B.B., Chen J.F., Masino S.A., Vaugeois J.M. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005, 45:385-412.
60. Furuyashiki T. Roles of dopamine and inflammation-related molecules in behavioral alterations caused by repeated stress. J Pharmacol Sci 2012, 120:63-69.
61. Gass N., Ollila H.M., Utge S., Partonen T., Kronholm E., Pirkola S., et al. Contribution of adenosine related genes to the risk of depression with disturbed sleep. J Affect Disord 2010, 126:134-139.
62. Gilliam F.G. Diagnosis and treatment of mood disorders in persons with epilepsy. Curr Opin Neurol 2005, 18:129-133.
63. Gimenez-Llort L., Fernandez-Teruel A., Escorihuela R.M., Fredholm B.B., Tobena A., Pekny M., et al. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002, 16:547-550.
64. Green E.K., Grozeva D., Raybould R., Elvidge G., Macgregor S., Craig I., et al. P2RX7: A bipolar and unipolar disorder candidate susceptibility gene?. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:1063-1069.
65. Grigoroiu-Serbanescu M., Herms S., Muhleisen T.W., Georgi A., Diaconu C.C., Strohmaier J., et al. Variation in P2RX7 candidate gene (rs2230912) is not associated with bipolar I disorder and unipolar major depression in four European samples. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:1017-1021.
66. Gunosewoyo H., Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat 2010, 20:625-646.
67. Halldner L., Aden U., Dahlberg V., Johansson B., Ledent C., Fredholm B.B. The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A receptors. Neuropharmacology 2004, 46:1008-1017.
68. Halmai Z., Dome P., Vereczkei A., Abdul-Rahman O., Szekely A., Gonda X., et al. Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms. J Affect Disord 2013, 150:104-109.
69. Hamdani N., Doukhan R., Kurtlucan O., Tamouza R., Leboyer M. Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep 2013, 15:387.
70. Hamilton S.P., Slager S.L., De Leon A.B., Heiman G.A., Klein D.F., Hodge S.E., et al. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004, 29:558-565.
71. Hamilton N., Vayro S., Kirchhoff F., Verkhratsky A., Robbins J., Gorecki D.C., et al. Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes. Glia 2008, 56:734-749.
72. Hansen O., Dimitrakoudi M. The relation of blood adenosine triphosphate to changes of mood in affective disorders. Br J Psychiatry 1974, 125:268-274.
73. Harvey M., Belleau P., Barden N. Gene interactions in depression: pathways out of darkness. Trends Genet 2007, 23:547-556.
74. Hedges D.W., Woon F.L., Hoopes S.P. Caffeine-induced psychosis. CNS Spectr 2009, 14:127-129.
75. Hejjas K., Szekely A., Domotor E., Halmai Z., Balogh G., Schilling B., et al. Association between depression and the Gln460Arg polymorphism of P2RX7 gene: a dimensional approach. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:295-299.
76. Hellmann-Regen J., Piber D., Hinkelmann K., Gold S.M., Heesen C., Spitzer C., et al. Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci 2013, 263(Suppl. 2):S123-S136.
77. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38:247-252.
78. Herzog A.G. Neuroactive properties of reproductive steroids. Headache 2007, 47(Suppl. 2):S68-S78.
79. Hirota T., Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res 2013, 149:88-95.
80. Hodgson R.A., Bertorelli R., Varty G.B., Lachowicz J.E., Forlani A., Fredduzzi S., et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009, 330:294-303.
81. Huang Z.L., Urade Y., Hayaishi O. The role of adenosine in the regulation of sleep. Curr Top Med Chem 2011, 11:1047-1057.
82. Iacob E., Light K.C., Tadler S.C., Weeks H.R., White A.T., Hughen R.W., et al. Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls. BMC Psychiatry 2013, 13:273.
83. Inoue K. The functions of ATP receptors in the hippocampus. Pharmacol Res 1998, 38:323-331.
84. Jahangard L., Soroush S., Haghighi M., Ghaleiha A., Bajoghli H., Holsboer-Trachsler E., et al. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur Neuropsychopharmacol 2014, 24:1210-1221.
85. Jenner F.A., Sampson G.A., Thompson E.A., Somerville A.R., Beard N.A., Smith A.A. Manic-depressive psychosis and urinary excretion of cyclic AMP. Br J Psychiatry 1972, 121:236-237.
86. Jerrell J.M., McIntyre R.S., Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry 2010, 71:1518-1525.
87. Jimenez-Pacheco A., Mesuret G., Sanz-Rodriguez A., Tanaka K., Mooney C., Conroy R., et al. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 2013, 54:1551-1561.
88. Jinnah H.A. Lesch-Nyhan disease: from mechanism to model and back again. Dis Model Mech 2009, 2:116-121.
89. Johansson B., Halldner L., Dunwiddie T.V., Masino S.A., Poelchen W., Gimenez-Llort L., et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci U S A 2001, 98:9407-9412.
90. Karve A.V., Jagtiani S.S., Chitnis K.A. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol 2013, 45:244-247.
91. Kaster M.P., Rosa A.O., Rosso M.M., Goulart E.C., Santos A.R., Rodrigues A.L. Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci Lett 2004, 355:21-24.
92. Kaster M.P., Santos A.R., Rodrigues A.L. Involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test. Brain Res Bull 2005, 67:53-61.
93. Kaster M.P., Ferreira P.K., Santos A.R., Rodrigues A.L. Effects of potassium channel inhibitors in the forced swimming test: possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res 2005, 165:204-209.
94. Kaster M.P., Rosa A.O., Santos A.R., Rodrigues A.L. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol 2005, 8:601-606.
95. Kaster M.P., Budni J., Santos A.R., Rodrigues A.L. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. Eur J Pharmacol 2007, 576:91-98.
96. Kaster M.P., Budni J., Binfare R.W., Santos A.R., Rodrigues A.L. The inhibition of different types of potassium channels underlies the antidepressant-like effect of adenosine in the mouse forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:690-696.
97. Kaster M.P., Budni J., Gazal M., Cunha M.P., Santos A.R., Rodrigues A.L. The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A 2A receptors. Purinergic Signal 2013, 9:481-486.
98. Kato T., Shioiri T., Takahashi S., Inubushi T. Measurement of brain phosphoinositide metabolism in bipolar patients using in vivo 31P-MRS. J Affect Disord 1991, 22:185-190.
99. Kato T., Takahashi S., Shioiri T., Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1992, 26:223-230.
100. Kato T., Takahashi S., Shioiri T., Inubushi T. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord 1993, 27:53-59.
101. Kato T., Shioiri T., Murashita J., Hamakawa H., Takahashi Y., Inubushi T., et al. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med 1995, 25:557-566.
102. Kato T., Kunugi H., Nanko S., Kato N. Association of bipolar disorder with the 5178 polymorphism in mitochondrial DNA. Am J Med Genet 2000, 96:182-186.
103. Kesebir S.O., Suner O., Yaylaci E.T., Bayrak A., Turan C. Increased uric acid levels in bipolar disorder: is it trait or state?. J Biol Regul Homeost Agents 2013, 27:981-988.
104. Kesebir S.O., Tatlidil Yaylaci E., Suner O., Gultekin B.K. Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: the role of affective temperament. J Affect Disord 2014, 165:131-134.
105. Kirshenbaum G.S., Saltzman K., Rose B., Petersen J., Vilsen B., Roder J.C. Decreased neuronal Na+, K+-ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. Genes Brain Behav 2011, 10:542-550.
106. Kish S.J., Fox I.H., Kapur B.M., Lloyd K., Hornykiewicz O. Brain benzodiazepine receptor binding and purine concentration in Lesch-Nyhan syndrome. Brain Res 1985, 336:117-123.
107. Kittner H., Franke H., Fischer W., Schultheis N., Krugel U., Illes P. Stimulation of P2Y1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: implications for the involvement of P2Y1 receptor-mediated nitric oxide production. Neuropsychopharmacology 2003, 28:435-444.
108. Klenke S., Kussmann M., Siffert W. The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenet Genomics 2011, 21:594-606.
109. Kondo D.G., Hellem T.L., Sung Y.H., Kim N., Jeong E.K., Delmastro K.K., et al. Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat 2011, 2011:650450.
110. Kraepelin E. Manic-depressive insanity and paranoia 1921, Chicago Medical Book Company, Chicago, IL.
111. Krugel U., Spies O., Regenthal R., Illes P., Kittner H. P2 receptors are involved in the mediation of motivation-related behavior. Purinergic Signal 2004, 1:21-29.
112. Kumaria A., Tolias C.M., Burnstock G. ATP signalling in epilepsy. Purinergic Signal 2008, 4:339-346.
113. Lam P., Hong C.J., Tsai S.J. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett 2005, 378:98-101.
114. Lang U.E., Lang F., Richter K., Vallon V., Hipp H.P., Schnermann J., et al. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Res 2003, 145:179-188.
115. Lavebratt C., Aberg E., Sjoholm L.K., Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 2010, 125:249-255.
116. Lazarus M., Shen H.Y., Cherasse Y., Qu W.M., Huang Z.L., Bass C.E., et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci 2011, 31:10067-10075.
117. Lekic D.M. Facilitation and antagonism of lidocaine-kindled seizures: the behavioral feature. Physiol Behav 1988, 42:83-85.
118. Lewin E., Bleck V. Electroshock seizures in mice: effect on brain adenosine and its metabolites. Epilepsia 1981, 22:577-581.
119. Ligthart L., Hottenga J.J., Lewis C.M., Farmer A.E., Craig I.W., Breen G., et al. Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders. Hum Genet 2013, 133:173-186.
120. Lin C., Tsai S.J., Hong C.J. Association analysis of a functional G protein beta3 subunit gene polymorphism (C825T) in mood disorders. Neuropsychobiology 2001, 44:118-121.
121. Lucae S., Salyakina D., Barden N., Harvey M., Gagne B., Labbe M., et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006, 15:2438-2445.
122. Lyngdoh T., Bochud M., Glaus J., Castelao E., Waeber G., Vollenweider P., et al. Associations of serum uric acid and SLC2A9 variant with depressive and anxiety disorders: a population-based study. PLoS One 2013, 8:e76336.
123. Lyoo I.K., Demopulos C.M., Hirashima F., Ahn K.H., Renshaw P.F. Oral choline decreases brain purine levels in lithium-treated subjects with rapid-cycling bipolar disorder: a double-blind trial using proton and lithium magnetic resonance spectroscopy. Bipolar Disord 2003, 5:300-306.
124. Machado-Vieira R. Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania. J Clin Psychopharmacol 2012, 32:735-736.
125. Machado-Vieira R., Lara D.R., Souza D.O., Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol 2001, 21:621-622.
126. Machado-Vieira R., Lara D.R., Souza D.O., Kapczinski F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses 2002, 58:297-304.
127. Machado-Vieira R., Soares J.C., Lara D.R., Luckenbaugh D.A., Busnello J.V., Marca G., et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008, 69:1237-1245.
128. Maillard M.C., Nikodijevic O., LaNoue K.F., Berkich D., Ji X.D., Bartus R., et al. Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists. J Pharm Sci 1994, 83:46-53.
129. Majumder P., Trujillo C.A., Lopes C.G., Resende R.R., Gomes K.N., Yuahasi K.K., et al. New insights into purinergic receptor signaling in neuronal differentiation, neuroprotection, and brain disorders. Purinergic Signal 2007, 3:317-331.
130. Mantere O., Soronen P., Uher R., Ketokivi M., Jylha P., Melartin T., et al. Neuroticism mediates the effect of P2RX7 on outcomes of mood disorders. Depress Anxiety 2012, 29:816-823.
131. Martin A., Boisgard R., Kassiou M., Dolle F., Tavitian B. Reduced PBR/TSPO expression after minocycline treatment in a rat model of focal cerebral ischemia: a PET study using [(18)F]DPA-714. Mol Imaging Biol 2011, 13:10-15.
132. McQuillin A., Bass N.J., Choudhury K., Puri V., Kosmin M., Lawrence J., et al. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry 2009, 14:614-620.
133. Minor T.R., Winslow J.L., Chang W.C. Stress and adenosine: II. Adenosine analogs mimic the effect of inescapable shock on shuttle-escape performance in rats. Behav Neurosci 1994, 108:265-276.
134. Moore C.M., Christensen J.D., Lafer B., Fava M., Renshaw P.F. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997, 154:116-118.
135. Nagy G., Ronai Z., Somogyi A., Sasvari-Szekely M., Rahman O.A., Mate A., et al. P2RX7 Gln460Arg polymorphism is associated with depression among diabetic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1884-1888.
136. Niklasson F., Agren H., Hallgren R. Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness?. J Neurol Neurosurg Psychiatry 1983, 46:255-260.
137. Northoff G. Gene, brains, and environment-genetic neuroimaging of depression. Curr Opin Neurobiol 2013, 23:133-142.
138. Ogawa N., Ueki H. Secondary mania caused by caffeine. Gen Hosp Psychiatry 2003, 25:138-139.
139. Oliveira Rda L., Seibt K.J., Rico E.P., Bogo M.R., Bonan C.D. Inhibitory effect of lithium on nucleotide hydrolysis and acetylcholinesterase activity in zebrafish (Danio rerio) brain. Neurotoxicol Teratol 2011, 33:651-657.
140. O'Neill M., Brown V.J. The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology (Berl) 2006, 184:46-55.
141. Pacher P., Nivorozhkin A., Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006, 58:87-114.
142. Pardo M., Lopez-Cruz L., Valverde O., Ledent C., Baqi Y., Muller C.E., et al. Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice. Behav Brain Res 2013, 247:217-226.
143. Paul S., Elsinga P.H., Ishiwata K., Dierckx R.A., van Waarde A. Adenosine A(1) receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging. Curr Med Chem 2011, 18:4820-4835.
144. Pereira V.S., Casarotto P.C., Hiroaki-Sato V.A., Sartim A.G., Guimaraes F.S., Joca S.R. Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: Involvement of nitric oxide. Eur Neuropsychopharmacol 2013, 23:1769-1778.
145. Phillis J.W. Potentiation of the action of adenosine on cerebral cortical neurones by the tricyclic antidepressants. Br J Pharmacol 1984, 83:567-575.
146. Phillis J.W., Kostopoulos G.K. Adenosine as a putative transmitter in the cerebral cortex. Studies with potentiators and antagonists. Life Sci 1975, 17:1085-1094.
147. Pinna A., Wardas J., Cozzolino A., Morelli M. Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology 1999, 20:44-51.
148. Popoli P., Benedetti M., Scotti de Carolis A. Anticonvulsant activity of carbamazepine and N6-L-phenylisopropyladenosine in rabbits. Relationship to adenosine receptors in central nervous system. Pharmacol Biochem Behav 1988, 29:533-539.
149. Porciuncula L.O., Vinade L., Wofchuk S., Souza D.O. Guanine based purines inhibit [(3)H]glutamate and [(3)H]AMPA binding at postsynaptic densities from cerebral cortex of rats. Brain Res 2002, 928:106-112.
150. Potucek Y.D., Crain J.M., Watters J.J. Purinergic receptors modulate MAP kinases and transcription factors that control microglial inflammatory gene expression. Neurochem Int 2006, 49:204-214.
151. Prediger R.D., Batista L.C., Takahashi R.N. Adenosine A1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice. Eur J Pharmacol 2004, 499:147-154.
152. Prichard J.W., Alger J.R., Turner R. Brain imaging: the NMR revolution. Interview by Clare Thompson. BMJ 1999, 319:1302.
153. Regenold W.T., Pratt M., Nekkalapu S., Shapiro P.S., Kristian T., Fiskum G. Mitochondrial detachment of hexokinase 1 in mood and psychotic disorders: implications for brain energy metabolism and neurotrophic signaling. J Psychiatr Res 2012, 46:95-104.
154. Renshaw P.F., Parow A.M., Hirashima F., Ke Y., Moore C.M., Frederick Bde B., et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 2001, 158:2048-2055.
155. Ring H.A., Heller A.J., Marshall W.J., Johnson A.L., Reynolds E.H. Plasma uric acid in patients receiving anticonvulsant monotherapy. Epilepsy Res 1991, 8:241-244.
156. Sadek A.R., Knight G.E., Burnstock G. Electroconvulsive therapy: a novel hypothesis for the involvement of purinergic signalling. Purinergic Signal 2011, 7:447-452.
157. Salamone J.D., Correa M. Dopamine/adenosine interactions involved in effort-related aspects of food motivation. Appetite 2009, 53:422-425.
158. Salvadore G., Viale C.I., Luckenbaugh D.A., Zanatto V.C., Portela L.V., Souza D.O., et al. Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:819-821.
159. Santos T.G., Souza D.O., Tasca C.I. GTP uptake into rat brain synaptic vesicles. Brain Res 2006, 1070:71-76.
160. Savelyev S.A., Rantamaki T., Rytkonen K.M., Castren E., Porkka-Heiskanen T. Sleep homeostasis and depression: studies with the rat clomipramine model of depression. Neuroscience 2012, 212:149-158.
161. Schmidt A.P., Lara D.R., Souza D.O. Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Ther 2007, 116:401-416.
162. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
163. Shen H.Y., Chen J.F. Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition. Curr Neuropharmacol 2009, 7:195-206.
164. Shen H.Y., Coelho J.E., Ohtsuka N., Canas P.M., Day Y.J., Huang Q.Y., et al. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci 2008, 28:2970-2975.
165. Shi X.F., Kondo D.G., Sung Y.H., Hellem T.L., Fiedler K.K., Jeong E.K., et al. Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: a phosphorus-31 magnetic resonance spectroscopy study. Bipolar Disord 2012, 14:607-617.
166. Shink E., Harvey M., Tremblay M., Gagne B., Belleau P., Raymond C., et al. Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region. Am J Med Genet B Neuropsychiatr Genet 2005, 135B:50-58.
167. Short J.L., Ledent C., Borrelli E., Drago J., Lawrence A.J. Genetic interdependence of adenosine and dopamine receptors: evidence from receptor knockout mice. Neuroscience 2006, 139:661-670.
168. Sikoglu E.M., Jensen J.E., Vitaliano G., Liso Navarro A.A., Renshaw P.F., Frazier J.A., et al. Bioenergetic measurements in children with bipolar disorder: a pilot 31P magnetic resonance spectroscopy study. PLoS One 2013, 8:e54536.
169. Skaper S.D., Debetto P., Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 2010, 24:337-345.
170. Smolen T.N., Smolen A. Purinergic modulation of ethanol-induced sleep time in long-sleep and short-sleep mice. Alcohol 1991, 8:123-130.
171. Soronen P., Mantere O., Melartin T., Suominen K., Vuorilehto M., Rytsala H., et al. P2RX7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:435-447.
172. Sperlagh B., Csolle C., Ando R.D., Goloncser F., Kittel A., Baranyi M. The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung 2012, 14:231-238.
173. Spinelli M.G. Neuroendocrine effects on mood. Rev Endocr Metab Disord 2005, 6:109-115.
174. Stone T.W., Taylor D.A. Antagonism by clonidine of neuronal depressant responses to adenosine, adenosine-5'-monophosphate and adenosine triphosphate. Br J Pharmacol 1978, 64:369-374.
175. Stone T.W., Ceruti S., Abbracchio M.P. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009, 535-587.
176. Sutin A.R., Cutler R.G., Camandola S., Uda M., Feldman N.H., Cucca F., et al. Impulsivity is associated with uric acid: evidence from humans and mice. Biol Psychiatry 2014, 75:31-37.
177. Taayedi R., Kohler C., Drendel V., Seidel B., Illes P., Krugel U. Purinergic mechanisms mediate depression-like responses to chronic stress. J Neurochem 2007, 102:288.
178. Tondo L., Rudas N. The course of a seasonal bipolar disorder influenced by caffeine. J Affect Disord 1991, 22:249-251.
179. Tosh D.K., Paoletta S., Deflorian F., Phan K., Moss S.M., Gao Z.G., et al. Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. J Med Chem 2012, 55:8075-8090.
180. Tsai S.J., Hong C.J., Hou S.J., Yen F.C. Association study of adenosine A2a receptor (1976C>T) genetic polymorphism and mood disorders and age of onset. Psychiatr Genet 2006, 16:185.
181. Ulrich H., Abbracchio M.P., Burnstock G. Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair. Stem Cell Rev 2012, 8:755-767.
182. Ushijima I., Mizuki Y., Hara T., Kaneyuki H., Mashimoto S., Kajimura N., et al. Effects of dilazep (Comelian) on the central purinergic system: inhibitory effects on clonidine-induced aggressive behavior. Eur J Pharmacol 1989, 161:245-248.
183. Vasileiou E., Montero R.M., Turner C.M., Vergoulas G. P2X(7) receptor at the heart of disease. Hippokratia 2010, 14:155-163.
184. Vavra V., Bhattacharya A., Jindrichova M., Zemkova H. Facilitation of neurotransmitter and hormone release by P2X purinergic receptors. InTech 2012, [Available from: http://www.intechopen.com/books/neuroscience-dealing-with-frontiers/facilitation-of-neurotransmitter-and-hormone-release-by-p2x-purinergic-receptors]. 10.5772/36279. C.M. Contreras (Ed.).
185. Viikki M., Kampman O., Anttila S., Illi A., Setala-Soikkeli E., Huuhka M., et al. P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. Neurosci Lett 2011, 493:127-130.
186. Vinade E.R., Izquierdo I., Lara D.R., Schmidt A.P., Souza D.O. Oral administration of guanosine impairs inhibitory avoidance performance in rats and mice. Neurobiol Learn Mem 2004, 81:137-143.
187. Von Lubitz D.K., Beenhakker M., Lin R.C., Carter M.F., Paul I.A., Bischofberger N., et al. Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. Eur J Pharmacol 1996, 302:43-48.
188. Wagner J.A., Katz R.J. Purinergic control of anxiety: direct behavioral evidence in the rat. Neurosci Lett 1983, 43:333-337.
189. Weber W.A., Dudley J., Lee J.H., Strakowski S.M., Adler C.M., DelBello M.P. A pilot study of alterations in high energy phosphoryl compounds and intracellular pH in unmedicated adolescents with bipolar disorder. J Affect Disord 2013, 150:1109-1113.
190. Wei C.J., Li W., Chen J.F. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 2011, 1808:1358-1379.
191. Weiser M., Burshtein S., Gershon A.A., Marian G., Vlad N., Grecu I.G., et al. Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord 2014, 16:441-447.
192. Weisman G.A., Woods L.T., Erb L., Seye C.I. P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential. CNS Neurol Disord Drug Targets 2012, 11:722-738.
193. Wen S., Cheng M., Wang H., Yue J., Wang H., Li G., et al. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem 2012, 45:49-53.
194. Williams-Karnesky R.L., Sandau U.S., Lusardi T.A., Lytle N.K., Farrell J.M., Pritchard E.M., et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest 2013, 123:3552-3563.
195. Woodson J.C., Minor T.R., Job R.F. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Behav Neurosci 1998, 112:399-409.
196. Wu P.H., Phillis J.W. Distribution and release of adenosine triphosphate in rat brain. Neurochem Res 1978, 3:563-571.
197. Yu C., Gupta J., Chen J.F., Yin H.H. Genetic deletion of A2A adenosine receptors in the striatum selectively impairs habit formation. J Neurosci 2009, 29:15100-15103.
198. Zezula J., Freissmuth M. The A(2A)-adenosine receptor: a GPCR with unique features?. Br J Pharmacol 2008, 153(Suppl. 1):S184-S190.
199. Zhang M.R., Kumata K., Maeda J., Yanamoto K., Hatori A., Okada M., et al. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med 2007, 48:1853-1861.
200. Zhang L., Su T.P., Choi K., Maree W., Li C.T., Chung M.Y., et al. P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res 2011, 45:435-441.
201. Zheng P., Chen J.J., Huang T., Wang M.J., Wang Y., Dong M.X., et al. A novel urinary metabolite signature for diagnosing major depressive disorder. J Proteome Res 2013, 12:5904-5911.
202. Zlomuzica A., Burghoff S., Schrader J., Dere E. Superior working memory and behavioural habituation but diminished psychomotor coordination in mice lacking the ecto-5'-nucleotidase (CD73) gene. Purinergic Signal 2013, 9:175-182.